Pfizer and French partner Valneva have begun a late-stage trial of a Lyme disease vaccine as evidence mounts that the tick-borne illness is rapidly spreading across the US and Europe.
The companies said on Monday they were recruiting 6,000 people aged five years and older for the phase 3 trial of the co-developed vaccine, the only Lyme disease jab undergoing tests on humans.
Almost half a million people every year are being diagnosed and treated for Lyme disease in the US, where it was first diagnosed in 1975, according to a study of insurance claims published last year by the Centers for Disease Control and Prevention.
您已阅读19%（626字），剩余81%（2593字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。